drugset / Trial / NCT04948125
Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a phase II study, to evaluate the effectiveness and safety of Camrelizumab combined with apatinib for advanced gastric or esophagogastric adenocarcinoma progressed after immune checkpoint inhibitors.
Timeline
- Start
- 2021-04-28
- Primary completion
- 2022-06-03
- Completion
- 2023-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | — |